Due its relative sensitivity to chemotherapy, there is substantial evidence that autologous HSCT is efficacious for patients with primary refractory or chemotherapy-sensitive recurrent malignant lymphomas of specific histologies, including "intermediate-grade" (e.g., disease diffuse large B-cell), NHL, and Hodgkin's lymphomas.105-108 The demonstration of a potent GVL effect against lymphomas is less clear, and the efficacy of DLI in lymphoma is anecdotal at best.47-49 When specific comparisons were made between syngeneic, autologous, and allogeneic HSCT in different types of lymphoma, a clear GVL effect was not demonstrated.48 Thus, the specific role of allogeneic HSCT has not been defined; however, there is evidence that non-myeloablative allogeneic HSCT may provide benefit for patients with recurrent follicular and advanced non-Hodgkin's lymphoma, as well as for Hodgkin's lymphoma.51,109

0 0

Post a comment